Transmedics Group Stock Today
| TMDX Stock | USD 76.04 3.30 4.16% |
Performance0 of 100
| Odds Of DistressLess than 28
|
TransMedics is trading at 76.04 as of the 25th of November 2024; that is 4.16 percent decrease since the beginning of the trading day. The stock's open price was 79.34. TransMedics has about a 28 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for TransMedics Group are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of December 2022 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 2nd of May 2019 | Category Healthcare | Classification Health Care |
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company was founded in 1998 and is headquartered in Andover, Massachusetts. The company has 33.56 M outstanding shares of which 8.43 M shares are at this time shorted by private and institutional investors with about 4.06 trading days to cover. More on TransMedics Group
Moving together with TransMedics Stock
Moving against TransMedics Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
TransMedics Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, SP Small-Cap 600, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsTransMedics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand TransMedics' financial leverage. It provides some insight into what part of TransMedics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TransMedics Group (TMDX) is traded on NASDAQ Exchange in USA. It is located in 200 Minuteman Road, Andover, MA, United States, 01810 and employs 584 people. TransMedics is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.55 B. TransMedics Group conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 33.56 M outstanding shares of which 8.43 M shares are at this time shorted by private and institutional investors with about 4.06 trading days to cover.
TransMedics Group currently holds about 204.46 M in cash with (13.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.41.
Check TransMedics Probability Of Bankruptcy
Ownership AllocationThe majority of TransMedics Group outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in TransMedics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in TransMedics Group. Please pay attention to any change in the institutional holdings of TransMedics Group as this could imply that something significant has changed or is about to change at the company.
Check TransMedics Ownership Details
TransMedics Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Eventide Asset Management, Llc | 2024-09-30 | 690.6 K | |
| Allspring Global Investments Holdings, Llc | 2024-06-30 | 569 K | |
| Mackenzie Investments | 2024-09-30 | 478.7 K | |
| Fuller & Thaler Asset Management Inc | 2024-09-30 | 456.5 K | |
| 1832 Asset Management L.p | 2024-09-30 | 455.4 K | |
| Bank Of New York Mellon Corp | 2024-06-30 | 420.7 K | |
| Sandhill Capital Partners Llc | 2024-09-30 | 392.6 K | |
| Fidelity International Ltd | 2024-06-30 | 376.8 K | |
| Man Group Plc | 2024-09-30 | 345.3 K | |
| Vanguard Group Inc | 2024-09-30 | 3.6 M | |
| Blackrock Inc | 2024-06-30 | 2.6 M |
TransMedics Historical Income Statement
TransMedics Stock Against Markets
TransMedics Corporate Management
| Miriam Provost | Vice Affairs | Profile | |
| Mark Anderson | Senior Development | Profile | |
| Susan Goodman | Vice Resources | Profile | |
| John Carey | VP Operations | Profile | |
| Nick Corcoran | Senior Operations | Profile | |
| Tamer MD | Chief Officer | Profile |
Additional Tools for TransMedics Stock Analysis
When running TransMedics' price analysis, check to measure TransMedics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TransMedics is operating at the current time. Most of TransMedics' value examination focuses on studying past and present price action to predict the probability of TransMedics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TransMedics' price. Additionally, you may evaluate how the addition of TransMedics to your portfolios can decrease your overall portfolio volatility.